SUSPECT ADVERSE REACTION REPORT

HN-Tolmar-TLM-2025-00561

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET		
		Day	Month	Year			Day	Month	Year
SFR	HONDURAS	16	Feb	1942	83	Male	07	Apr	2025

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Respiratory distress (Respiratory distress (10038687), Respiratory distress (10038687))
Not Recovered/Not Resolved/Ongoing
2) Renal cyst suggestive of study (Renal cyst (10038423), Renal cyst (10038423))
(07/Apr/2025 -) - Not Recovered/Not Resolved/Ongoing
3) Complete lipid profile elevation (Abnormal lipid profile (10000157), Lipids abnormal (10024588))
(07/Apr/2025 -) - Not Recovered/Not Resolved/Ongoing
4) Weight gain (Abnormal weight gain (10000188), Abnormal weight gain (10000188))
Not Recovered/Not Resolved/Ongoing

Cont..

8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☑ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (45 Milligram, Injection)(L15276CUY)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)

1) (45 milligram(s), 1 in 24 Week)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Prostate cancer [10060862 - Prostate cancer]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (18/Oct/2024 - Ongoing)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

1)LEVOTHYROXIN(LEVOTHYROXINE SODIUM)

Cont..

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes)

Cont..

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
debbie.maierhofer@tolmar.comand+1-4129158447

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	HN-Tolmar-TLM-2025-00561
24c. DATE RECEIVED BY MANUFACTURER: 08/Apr/2025	24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT: 19/Apr/2025	25a. REPORT TYPE: ☑ INITIAL ☐ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

5) Discomfort when urinating (Dysuria (10013990), Dysuria (10013990) - Not Recovered/Not Resolved/Ongoing)

Event Description :

This study report from Honduras was received by Adium via the Patients Support Program (reference number: HN-ADIUM-HN-0149-20250408) on 08-Apr-2025 from a consumer (patient's family member) (non-healthcare professional) regarding an elderly 83-years-old male patient who experienced serious(medically significant) event of ‘respiratory distress' (respiratory distress) and non- serious events of ‘renal cyst suggestive of study' (renal cyst), ‘complete lipid profile elevation' (Lipids abnormal), ‘weight gain' (abnormal weight gain) and ‘discomfort when urinating' (dysuria) during Eligard (leuprolide acetate) 45 milligram therapy for prostate cancer. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 09-Apr-2025.

The patient's medical history included glucose tolerance impaired, COVID-19, respiratory failure and obesity and current conditions included prostate cancer, hypertension and dyslipidaemia.

Concomitant medications included atorvastatin, levothyroxine, irbesartan, metformin and supplemental oxygen.

On 18-Oct-2024, the patient began receiving Eligard 45 mg, every 24 weeks via subcutaneous route for prostate cancer (Lot numbers: L15276CUY and Expiration dates: Aug-2026).

On an unknown date, the patient had gained weight and experienced respiratory distress. His family commented that the patient lived in another apartment and did not know how he was feeding, oxygen dependent patient as a result of post-COVID.

Corrective treatment was unknown.

Relevant test results included:
On 07-Apr-2025: Ultrasound abdomen: Abdominal ultrasound finding revealed a renal cyst (Ref. range: Not provided).
07-Apr-2025: Lipids: Elevation of the complete lipid profile (Ref. range: Not provided).
On an unknown date: PSA: 0.4 ng/ml (Ref. range: Not provided).
On an unknown date: Weight: abnormal weight gain (Ref. range: Not provided).

Action taken with Eligard in response to the events was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of renal cyst, lipids abnormal, abnormal weight gain, respiratory distress and dysuria were not resolved.

The reporter did not assess the seriousness of renal cyst, lipids abnormal, abnormal weight gain, respiratory distress and dysuria.

The reporter did not provide the causality of renal cyst, lipids abnormal, abnormal weight gain, respiratory distress and dysuria in relationship to Eligard and Eligard unspecified device.

No follow up query was raised.

Listedness
Respiratory distress >Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
Respiratory distress> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
Respiratory distress> Eligard®>unlisted as per USPI Eligard®>Feb-2025
Respiratory distress> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Renal cyst >Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
Renal cyst > Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
Renal cyst > Eligard®>unlisted as per USPI Eligard®>Feb-2025
Renal cyst > Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Lipids abnormal >Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
Lipids abnormal> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
Lipids abnormal> Eligard®>unlisted as per USPI Eligard®>Feb-2025
Lipids abnormal> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Abnormal weight gain>Eligard® >listed as per CCDS Eligard®> 7-Nov-2024
Abnormal weight gain> Eligard® >listed as per Canadian Monograph Eligard®> 2-Apr-2025
Abnormal weight gain> Eligard®>listed as per USPI Eligard®>Feb-2025
Abnormal weight gain> Eligard® Unspecified Device> listed as per USPI Eligard®>Feb-2025

Dysuria>Eligard® >listed as per CCDS Eligard®> 7-Nov-2024
Dysuria> Eligard® >listed as per Canadian Monograph Eligard®> 2-Apr-2025
Dysuria> Eligard®>listed as per USPI Eligard®>Feb-2025
Dysuria> Eligard® Unspecified Device> listed as per USPI Eligard®>Feb-2025

Continuation Sheet for CIOMS report

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This case is regarding an elderly 83-year-old male who reported serious (medically significant) event of 'respiratory distress' (respiratory distress) and non- serious events of renal cyst (renal cyst suggestive of study), Lipids abnormal (complete lipid profile elevation), abnormal weight gain (weight gain) and dysuria (discomfort when urinating) during Eligard (leuprolide acetate) 45 milligram therapy for prostate cancer. Tolmar assessed the event respiratory distress as serious as it is included in IME list and rest of the reported events as non-serious since they did not meet the ICH seriousness criteria. The causality of event respiratory distress was assessed as not related to suspect Eligard(drug and device) considering the nature of the event and it could be secondary to COVID-19 infection and medical history of respiratory failure and obesity could be risk factors for the event. The causality of events renal cyst and lipids abnormal was assessed as not related to suspect Eligard(drug and device) considering the nature of the events, etiopathogenesis and inconsistency with drug profile and medical history of dyslipidaemia could be a risk factor for event lipids abnormal. The causality of events abnormal weight gain and dysuria was assessed as not related to suspect Eligard(drug and device) as it could be due to elderly age, obesity could be a confounding factor for abnormal weight gain and renal cyst could be a risk factor for dysuria.

Additional Information (Continuation...)

Lab Result :

Test Name	Test Date	Test Result	Normal Value
LIPIDS	07/Apr/2025		
PSA	07/Apr/2025	0.4 nanogram per millliter	
ULTRASOUND ABDOMEN	07/Apr/2025		
WEIGHT			

Test Result (Code) / Result Unstructured Data (free text) :

1) Test Name: LIPIDS

Result Unstructured Data (free text) : Elevation of the complete lipid profile

Test Date: 07/Apr/2025

3) Test Name: ULTRASOUND ABDOMEN

Result Unstructured Data (free text) : Abdominal ultrasound finding revealed a renal cyst

Test Date: 07/Apr/2025

4) Test Name: WEIGHT

Result Unstructured Data (free text) : abnormal Weight gain

Test Date:

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug : Eligard® (Leuprolide acetate)
- Active Substance : 1) Leuprolide acetate
- Drug Characterization : Suspect
- Form Strength : 1) 45 Milligram
- Form of Admin : 1) Injection
- Lot Number : 1) L15276CUY
- Daily Dose : (45 milligram(s), 1 in 24 Week)
- Route of Admin : 1) Subcutaneous
- Indications : 1) Prostate cancer [10060862 - Prostate cancer]
- Therapy Dates : 1) From : 18/Oct/2024 To :Continuing
- Action(s) Taken With Drug : Dose not changed

Causality

1) Respiratory distress (Respiratory distress - 10038687, Respiratory distress - 10038687)
- Causality as per reporter : Not Reported
- Causality as per Mfr : Not Related
- DeChallenge : Not applicable
- ReChallenge : Not Applicable

2) Renal cyst suggestive of study (Renal cyst - 10038423, Renal cyst - 10038423)

Continuation Sheet for CIOMS report

Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

3) Complete lipid profile elevation (Abnormal lipid profile - 10000157, Lipids abnormal - 10024588)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

4) Weight gain (Abnormal weight gain - 10000188, Abnormal weight gain - 10000188)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

5) Discomfort when urinating (Dysuria - 10013990, Dysuria - 10013990)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Respiratory distress
CORE UnLabeled
2) Renal cyst suggestive of study
CORE UnLabeled
3) Complete lipid profile elevation
CORE UnLabeled
4) Weight gain
CORE Labeled
5) Discomfort when urinating
CORE Labeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) L15276CUY
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Action(s) Taken With Drug : Not applicable

Causality

1) Respiratory distress (Respiratory distress - 10038687, Respiratory distress - 10038687)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

2) Renal cyst suggestive of study (Renal cyst - 10038423, Renal cyst - 10038423)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

3) Complete lipid profile elevation (Abnormal lipid profile - 10000157, Lipids abnormal - 10024588)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

4) Weight gain (Abnormal weight gain - 10000188, Abnormal weight gain - 10000188)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

5) Discomfort when urinating (Dysuria - 10013990, Dysuria - 10013990)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Continuation Sheet for CIOMS report

Labeling :

1) Respiratory distress
   CORE
2) Renal cyst suggestive of study
   CORE
3) Complete lipid profile elevation
   CORE
4) Weight gain
   CORE
5) Discomfort when urinating
   CORE

15. DAILY DOSE(S) (Continuation...)

Dosage Text :

Drug 1 :Eligard®

1) Eligard 45mg x1 LIO x 1JER

22.CONCOMITANT DRUG(S) (Continuation...)

1). Drug	:	LEVOTHYROXIN
Active Substance	:	1) LEVOTHYROXINE SODIUM
Form Strength	:	
Daily Dose	:	1) (75 milligram(s), in 1 Day)
Indications	:	1) Product used for unknown indication [10070592 - Product used for unknown indication]

2). Drug	:	METFORMIN
Active Substance	:	1) METFORMIN
Form Strength	:	
Daily Dose	:	1) (1000 milligram(s), in 1 Day)
Indications	:	1) Product used for unknown indication [10070592 - Product used for unknown indication]

3). Drug	:	Supplemental oxygen due to respiratory insufficiency
Active Substance	:	1) OTHER THERAPEUTIC PRODUCTS
Form Strength	:	
Indications	:	1) Respiratory insufficiency [10038701 - Respiratory insufficiency]
Dosage Text	:	1) Patient uses supplemental oxygen due to respiratory insufficiency - post covid sequelae.

4). Drug	:	IRBESARTAN
Active Substance	:	1) IRBESARTAN
Form Strength	:	
Daily Dose	:	1) (300 milligram(s), in 1 Day)
Indications	:	1) Product used for unknown indication [10070592 - Product used for unknown indication]

5). Drug	:	ATORVASTATIN
Active Substance	:	1) ATORVASTATIN
Form Strength	:	
Indications	:	1) Product used for unknown indication [10070592 - Product used for unknown indication]

23. OTHER RELEVANT HISTORY (Continuation...)

2) PRE DIABETES (10065542 , Prediabetes) (Continuing : Unknown)

3) ARTERIAL HYPERTENSION (10081425 , Arterial hypertension) (Continuing : YES)

4) MIXED DYSLIPIDEMIA (10058108 , Dyslipidaemia) (Continuing : YES)

5) RESPIRATORY INSUFFICIENCY (10038701 , Respiratory insufficiency) (Continuing : Unknown)

6) OBESITY (10029883 , Obesity) (Continuing : Unknown)

7) COVID (10084268 , COVID-19) (Continuing : NO)